In Vitro Degradation of Borosilicate Bioactive Glass and Poly(l-lactide-co-ε-caprolactone) Composite Scaffolds.

Composite scaffolds were obtained by mixing various amounts (10, 30 and 50 weight % [wt %]) of borosilicate bioactive glass and poly(l-lactide-co-ε-caprolactone) (PLCL) copolymer. The composites were foamed using supercritical CO2. An increase in the glass content led to a decrease in the pore size and density. In vitro dissolution/reaction test was performed in simulated body fluid. As a function of immersion time, the solution pH increased due to the glass dissolution. This was further supported by the increasing amount of Ca in the immersing solution with increasing immersion time and glass content. Furthermore, the change in scaffold mass was significantly greater with increasing the glass content in the scaffold. However, only the scaffolds containing 30 and 50 wt % of glasses exhibited significant hydroxyapatite (HA) formation at 72 h of immersion. The compression strength of the samples was also measured. The Young's modulus was similar for the 10 and 30 wt % glass-containing scaffolds whereas it increased to 90 MPa for the 50 wt % glass containing scaffold. Upon immersion up to 72 h, the Young's modulus increased and then remained constant for longer immersion times. The scaffold prepared could have great potential for bone and cartilage regeneration.

An in vitro study of composites of poly(L-lactide-co-ε-caprolactone), ß-tricalcium phosphate and ciprofloxacin intended for local treatment of osteomyelitis.

Osteomyelitis is a bacterial disease that can become chronic, and treatment often includes a surgical operation to remove infected bone. The aim of this study was to develop and investigate in vitro bone filling composite materials that release ciprofloxacin to kill any remaining bacteria and contain bioceramic to help the bone to heal. Three composites of poly(L-lactide-co-ε-caprolactone), ß-tricalcium phosphate and ciprofloxacin were compounded using twin-screw extrusion and sterilized by gamma irradiation. Drug release and degradation of the composites were investigated in vitro for 52 weeks. The composite with 50 wt% of ß-TCP had the most promising ciprofloxacin release profile. The ceramic component accelerated the drug release that occurred in three phases obeying first-order kinetics. Inhibition zone testing using bioluminescence showed that the released ciprofloxacin had effect in eradicating a common osteomyelitis causing bacteria Pseudomonas aeruginosa. During the in vitro degradation test series, molar weight of the polymer matrix of the composites decreased rapidly. Additionally, (1)H-NMR analysis showed that the polymer had blocky structure and the comonomer ratio changed during hydrolysis. The tested composites showed great potential to be developed into bone filler materials for the treatment of osteomyelitis or other bone related infections.

Hydrolytic degradation of composites of poly(L-lactide-co-epsilon-caprolactone) 70/30 and ß-tricalcium phosphate.

There is an increasing need for synthetic bone substitute materials that decrease the need for allografts and autografts. In this study, composites of ß-tricalcium phosphate and a biodegradable poly(L-lactide-co-ε-caprolactone) were manufactured using extrusion to form biodegradable composites with high ß-tricalcium phosphate contents for osteoconductivity. The hydrolytic degradation of the composites containing 0, 10, 20, 35 and 50% of ß-tricalcium phosphate was studied in vitro for 52 weeks. During the study, it was observed that ß-tricalcium phosphate did not have an effect on the degradation rate of the polymer matrix. However, the crystallinity of the materials increased throughout the test series and changes in glass transition temperatures were also observed as the comonomer ratio of the polymer matrix changed as the degradation proceeded. The results show that the materials have desirable degradation properties and, thus, possess great potential as bioabsorbable and osteoconductive bone filling materials.

Processing and sustained in vitro release of rifampicin containing composites to enhance the treatment of osteomyelitis.

The objective in this study was to develop an osteoconductive, biodegradable and rifampicin releasing bone filling composite material for the treatment of osteomyelitis, a bacterial infection of bone that is very difficult and expensive to treat. The composite material will be used together with a ciprofloxacin releasing composite, because of the rapid development of resistant bacteria when rifampicin is used alone. Three composites were manufactured by twin-screw extrusion. The polymer matrix for the composites was poly(L-lactide-co-ε-caprolactone) 70/30 and all the composites contained 8 wt% (weight percent) of rifampicin antibiotic. The ß-TCP contents of the composites were 0 wt%, 50 wt% and 60 wt%. The composites were sterilized by gamma irradiation before in vitro degradation and drug release tests. The hydrolytical degradation of the studied composites proceeded quickly and the molecular weight of the polymer component of the composites decreased rapidly. Rifampicin release occurred in four phases in which the high ß-TCP content of the samples, polymer degradation and mass loss all played a role in determining the phases. The ceramic component was seen to have a positive effect on the drug release. The composite with 50 wt% of ß-TCP showed the most promising rifampicin release profile and it also showed activity against a common osteomyelitis causing bacteria Pseudomonas aeruginosa. A clear inhibition zone was formed in 16 h incubation. Overall, the tested materials showed great potential to be developed into a bone filler material for the treatment of osteomyelitis or other bone related infections in combination with the ciprofloxacin releasing materials.